C12-Ceramide

C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease[1][1].

Product Specifications

CAS Number

[74713-60-3]

Product Name Alternative

N-Lauroyl-D-erythro-sphingosine; N-Laurylsphingosine

UNSPSC

12352211

Hazard Statement

H225, H319

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/c12-ceramide.html

Purity

99.82

Solubility

DMSO : 2.5 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O

Molecular Formula

C30H59NO3

Molecular Weight

481.79

Precautions

H225, H319

References & Citations

[1]He X, et, al. A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal Biochem. 2003 Mar 1;314 (1) :116-20.|[2]Øverbye A, et, al. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget. 2017 Aug 12;8 (44) :76921-76934.